https://www.selleckchem.com/pr....oducts/ziftomenib.ht
The MTD was not determined because the geometric mean AUC values of romidepsin in moderate (7 mg/m ) and severe (5 mg/m ) impairment cohort were 114% and 116% of the normal cohort (14 mg/m ). Data from the ETCTN-9008 trial led to changes in the romidepsin labeling to reflect starting dose adjustment for patients with cancer and moderate and severe hepatic impairment, with no adjustment for mild hepatic impairment. Data from the ETCTN-9008 trial led to changes in the romidepsin labeling to reflect starting dose adjustment for patients
Like
Comment
Share
